Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05910801 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Study acronym: V-MIND
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 2 of 2 sitesv7
  2. Study sites: 1 to 2v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 29, 2023 to Jan 4, 2024
    • Site details revised
    v5
  4. Start date: Nov 11, 2023 to Dec 29, 2023v4
  5. Start date: Jul 11, 2023 to Nov 11, 2023v3
  6. Start date: Jul 1, 2023 to Jul 11, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab, lenalidomide and venetoclax together may kill cancer cells more efficiently in patients with relapsed or refractory mantle cell lymphoma.
Trial Details
NCT Number NCT05910801
Lead Sponsor Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Related terms Lymphoma, Mantle-Cell
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov